Not recruiting
Myelofibrosis
Not recruitingStudy of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
Registered drugNo placebo
Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
Registered drugNo placebo
- Disease:Myelofibrosis
- Substances:Alkylating agentsAntimetabolites+2
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Alkylating agents



